L. F. Reichardt, Neurotrophin-regulated signalling pathways, Philos Trans R Soc Lond B Biol Sci, vol.361, p.16939974, 1473.

A. Nakagawara, Trk receptor tyrosine kinases: a bridge between cancer and neural development, Cancer Lett, vol.169, issue.2, p.11431098, 2001.

A. Vaishnavi, A. T. Le, and R. C. Doebele, TRKing down an old oncogene in a new era of targeted therapy. Cancer discovery, vol.5, p.4293234, 2014.

A. L. Genevois, G. Ichim, M. M. Coissieux, M. P. Lambert, F. Lavial et al., Dependence receptor TrkC is a putative colon cancer tumor suppressor, Proc Natl Acad Sci, vol.110, issue.8, p.3581924, 2013.

S. Tauszig-delamasure and J. Bouzas-rodriguez, Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy, Expert opinion on therapeutic targets, vol.15, issue.7, p.21473736, 2011.

Y. Luo, A. M. Kaz, S. Kanngurn, P. Welsch, S. M. Morris et al., NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer, PLoS Genet, vol.9, issue.7, p.3708790, 2013.

P. Mehlen and S. Tauszig-delamasure, Dependence receptors and colorectal cancer. Gut, vol.63, issue.11, p.25163468, 2014.

W. M. Grady, Context is everything for dependence receptors in colorectal cancer, Proc Natl Acad Sci U S A, vol.110, issue.8, p.3581887, 2013.

S. Tauszig-delamasure, L. Y. Yu, J. R. Cabrera, J. Bouzas-rodriguez, C. Mermet-bouvier et al., The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm, Proc Natl Acad Sci, vol.104, issue.33, p.17686986, 2007.

V. Nikoletopoulou, H. Lickert, J. M. Frade, C. Rencurel, P. Giallonardo et al., Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not, Nature, vol.467, issue.7311, pp.59-63, 2010.

B. Gibert and P. Mehlen, Dependence Receptors and Cancer: Addiction to Trophic Ligands, Cancer Res, vol.75, issue.24, p.26627011, 2015.

J. Bouzas-rodriguez, J. R. Cabrera, C. Delloye-bourgeois, G. Ichim, J. G. Delcros et al., Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC
URL : https://hal.archives-ouvertes.fr/hal-00475272

, J Clin Invest, vol.120, issue.3, pp.850-858, 2010.

G. Ichim, A. L. Genevois, M. Menard, L. Y. Yu, J. M. Coelho-aguiar et al., The dependence receptor TrkC triggers mitochondria-dependent apoptosis upon Cobra-1 recruitment, Mol Cell, vol.51, issue.5, p.24034695, 2013.

D. A. Jans, C. Y. Xiao, and M. H. Lam, Nuclear targeting signal recognition: a key control point in nuclear transport?, Bioessays, vol.22, issue.6, 2000.

Y. M. Chook and G. Blobel, Karyopherins and nuclear import. Current opinion in structural biology, vol.11, pp.703-718, 2001.

D. Goldschneider, N. Rama, C. Guix, and P. Mehlen, The neogenin intracellular domain regulates gene transcription via nuclear translocation, Mol Cell Biol, vol.28, issue.12, p.18391016, 2008.

Y. Taniguchi, S. H. Kim, and S. S. Sisodia, Presenilin-dependent "gamma-secretase" processing of deleted in colorectal cancer (DCC), J Biol Chem, vol.278, issue.33, p.12840034, 2003.

R. L. Davis and D. L. Turner, Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning, Oncogene, vol.20, issue.58, p.11840327, 2001.

A. Fischer, N. Schumacher, M. Maier, M. Sendtner, and M. Gessler, The Notch target genes Hey1 and Hey2 are required for embryonic vascular development, Genes Dev, vol.18, issue.8, p.395849, 2004.

B. Belandia, S. M. Powell, J. M. Garcia-pedrero, M. M. Walker, C. L. Bevan et al., Hey1, a mediator of notch signaling, is an androgen receptor corepressor, Mol Cell Biol, vol.25, issue.4, p.548017, 2005.

T. Van-maerken, F. Speleman, J. Vermeulen, I. Lambertz, D. Clercq et al., Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma, Cancer Res, vol.66, issue.19, p.17018622, 2006.

J. Carr, E. Bell, A. D. Pearson, U. R. Kees, H. Beris et al., Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse, Cancer Res, vol.66, issue.4, p.16489014, 2006.

Q. Huang, A. Raya, P. Dejesus, S. H. Chao, K. C. Quon et al., Identification of p53 regulators by genome-wide functional analysis, Proc Natl Acad Sci U S A, vol.101, issue.10, p.373483, 2004.

I. Rhee, K. E. Bachman, B. H. Park, K. W. Jair, R. W. Yen et al., DNMT1 and DNMT3b cooperate to silence genes in human cancer cells, Nature, vol.416, issue.6880, p.11932749, 2002.
DOI : 10.1038/416552a

P. G. Komarov, E. A. Komarova, R. V. Kondratov, K. Christov-tselkov, J. S. Coon et al., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy, Science, vol.285, issue.5434, p.10481009, 1999.

J. Heisig, D. Weber, E. Englberger, A. Winkler, S. Kneitz et al., Target gene analysis by microarrays and chromatin immunoprecipitation identifies HEY proteins as highly redundant bHLH repressors, PLoS Genet, vol.8, issue.5, p.3355086, 2012.
DOI : 10.1371/journal.pgen.1002728

URL : https://journals.plos.org/plosgenetics/article/file?id=10.1371/journal.pgen.1002728&type=printable

D. Weber, J. Heisig, S. Kneitz, E. Wolf, M. Eilers et al., Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes, Journal of molecular and cellular cardiology, vol.79, p.25446183, 2015.

D. Weber, C. Wiese, and M. Gessler, Hey bHLH transcription factors, Curr Top Dev Biol, vol.110, p.25248480, 2014.
DOI : 10.1016/b978-0-12-405943-6.00008-7

K. Botcheva, S. R. Mccorkle, W. R. Mccombie, J. J. Dunn, and C. W. Anderson, Distinct p53 genomic binding patterns in normal and cancer-derived human cells, Cell Cycle, vol.10, issue.24, p.3272258, 2011.
DOI : 10.4161/cc.10.24.18383

URL : http://europepmc.org/articles/pmc3272258?pdf=render

W. S. El-deiry, S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein, Definition of a consensus binding site for p53, Nat Genet, vol.1, issue.1, p.1301998, 1992.

T. Miyashita and J. C. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell, vol.80, issue.2, pp.293-302, 1995.

V. Graupner, A. E. Overkamp, T. Rothfuss, O. , D. Laurenzi et al., Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level, Cell Death Differ, vol.18, issue.7, p.21233848, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00608717

P. Central and P. , , p.3131957

D. G. Stupack, T. Teitz, M. D. Potter, D. Mikolon, P. J. Houghton et al., Potentiation of neuroblastoma metastasis by loss of caspase-8, Nature, vol.439, issue.7072, pp.95-104, 2006.

G. M. Brodeur, A. Nakagawara, D. J. Yamashiro, N. Ikegaki, X. G. Liu et al., Expression of TrkA, TrkB and TrkC in human neuroblastomas, J Neurooncol, vol.31, issue.1-2, p.9049830, 1997.

I. Revet, G. Huizenga, A. Chan, J. Koster, R. Volckmann et al., The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma, Exp Cell Res, vol.314, issue.4, p.18201699, 2008.

C. Wang, B. Gong, P. R. Bushel, J. Thierry-mieg, D. Thierry-mieg et al., The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance, Nat Biotechnol, vol.32, issue.9, p.4243706, 2014.
DOI : 10.1038/nbt.3001

URL : http://europepmc.org/articles/pmc4243706?pdf=render

I. Janoueix-lerosey, D. Lequin, L. Brugieres, A. Ribeiro, L. De-pontual et al., Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, vol.455, issue.7215, pp.967-70, 2008.

S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt, Apoptosis-the p53 network, J Cell Sci, vol.116, p.12972501, 2003.
DOI : 10.1242/jcs.00739

J. M. Maris, M. D. Hogarty, R. Bagatell, S. L. Cohn, and . Neuroblastoma, Lancet, vol.369, issue.9579, p.17586306, 2007.

M. P. Dekkers and Y. A. Barde, Programmed cell death in neuronal development, Science, vol.340, issue.6128, p.23559240, 2013.

Y. Wakamatsu, Y. Watanabe, H. Nakamura, and H. Kondoh, Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation, Development, vol.124, issue.10, p.9169842, 1997.

L. M. Hansford, W. D. Thomas, J. M. Keating, C. A. Burkhart, A. E. Peaston et al., Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification, Proc Natl Acad Sci U S A, vol.101, issue.34, p.15314226, 2004.

P. Central and P. , , p.515113

G. Alam, H. Cui, H. Shi, L. Yang, J. Ding et al., MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development, Am J Pathol, vol.175, issue.2, p.2716980, 2009.

A. Cazes, L. Lopez-delisle, K. Tsarovina, C. Pierre-eugene, D. Preter et al., Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALKmutated neuroblastoma, Oncotarget, vol.5, issue.9, p.4058037, 2014.

F. Marmigere and P. Ernfors, Specification and connectivity of neuronal subtypes in the sensory lineage, Nat Rev Neurosci, vol.8, issue.2, pp.114-141, 2007.

A. Mukhopadhyay, J. Jarrett, T. Chlon, and J. A. Kessler, HeyL regulates the number of TrkC neurons in dorsal root ganglia, Dev Biol, vol.334, issue.1, pp.142-51, 2009.

G. Barone, D. A. Tweddle, J. M. Shohet, L. Chesler, L. Moreno et al., MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance, Current drug targets, vol.15, issue.1, p.24387312, 2014.

J. Imamura, C. R. Bartram, F. Berthold, D. Harms, H. Nakamura et al., Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification, Cancer Res, vol.53, issue.17, p.8358734, 1993.

H. Komuro, Y. Hayashi, M. Kawamura, K. Hayashi, Y. Kaneko et al., Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas, Cancer Res, vol.53, issue.21, p.8221663, 1993.

K. Vogan, M. Bernstein, J. M. Leclerc, L. Brisson, J. Brossard et al., Absence of p53 gene mutations in primary neuroblastomas, Cancer Res, vol.53, issue.21, p.8221661, 1993.

J. Carr-wilkinson, O. 'toole, K. Wood, K. M. Challen, C. C. Baker et al., High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma, Clin Cancer Res, vol.16, issue.4, p.2842933, 2010.

J. J. Manfredi, The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor, Genes Dev, vol.24, issue.15, p.2912554, 2010.

M. P. Khoury and J. C. Bourdon, The isoforms of the p53 protein. Cold Spring Harbor perspectives in biology, vol.2, p.2829963, 2010.

H. Kocak, S. Ackermann, B. Hero, Y. Kahlert, A. Oberthuer et al., Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma, Cell death & disease, vol.4, p.3668636, 2013.

V. Bewick, L. Cheek, and J. Ball, Statistics review 12: survival analysis, Critical care, vol.8, issue.5, p.1065034, 2004.